OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
- MHRA seeks to harmonize UK & US regulatory review via Project Orbis EMA Rapporteur Scientific Advice Meeting scheduled for October 2025 New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it held a successful Scientific Advice Meeting with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) in July and has submitted an invited Innovative Licensing and Access Pathway (ILAP) application to begin the regulatory process towards approval of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. MHRA suggested applying for Project Orbis at the time of regulatory approval submission to synchronize its Marketing Authorization Application process with the United States Food & Drug Administration's (FDA) Biologics Licensing Application (BLA) Accelerated Approval Program.
- 08/07/2025
|
Ostin Technology Group Co., Ltd. Announces 1-for-25 Reverse Share Split Effective August 5, 2025
- Nanjing, China, July 28, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (NASDAQ:OST), a leading supplier of display modules and polarizers based in China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-25 (the "The Reverse Share Split"). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on July 17, 2025. The Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on August 5, 2025, under the existing ticker symbol "OST." The new CUSIP number for the Company's Class A ordinary shares will be G67927122.
- 07/28/2025
|
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it was granted an End of Phase 2 Meeting by the United States Food & Drug Administration (“FDA”) to review the OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. The Company expects the meeting to occur in the third quarter of 2025. The En.
- 07/03/2025
|
Univest Securities, LLC Announces Closing of $5 Million Registered Direct Offering for its Client Ostin Technology Group Co., Ltd. (Nasdaq: OST)
- New York, July 01, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”), for its client Ostin Technology Group Co., Ltd. (Nasdaq: OST) (the “Company”), a leading supplier of display modules and polarizers based in China.
- 07/01/2025
|
Ostin Technology Group Co., Ltd. Announces $5 Million Registered Direct Offering
- Nanjing, China, June 30, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 41,666,667 of the Company's Class A ordinary share, par value $0.001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.12 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.001 per share.
- 06/30/2025
|
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive 1-year event free survival (EFS), overall survival and safety clinical trial data updates from the 40 patient treatment arm of its Phase 2b clinical trial of immunotherapy candidate OST-HER2 in the prevention or delay of recurrence in fully resected, lung metastatic osteosarcoma. In data pre.
- 06/30/2025
|
Ostin Technology Group Co Ltd Issues Statement Regarding Market Activity
- Nanjing, China, June 27, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, issued the following statement in response to the market activity on June 26:
- 06/27/2025
|
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it received positive written feedback from the US Food & Drug Administration (“FDA”) Type D Meeting that occurred in mid-June 2025 regarding endpoints required to support an Accelerated Approval Program marketing application for its Phase 2b trial of OST-HER2 in the prevention or delay of re.
- 06/24/2025
|
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for.
- 06/06/2025
|
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma. OST-HER2 market opportunity in canine osteosarcoma exceeds $150 million Recent data in prevention of amputation in frontline canine osteosarcoma and control of.
- 05/15/2025
|
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the issuance of United States Patent #12,230,738 protecting proprietary commercial manufacturing methods for the Company's listeria monocytogenes (Lm) cancer immunotherapy platform technology into 2040. The Company is seeking to gain FDA approval for lead asset OST-HER2 in the treatment of pediatric.
- 05/07/2025
|
Ostin Technology Group Announces Pricing of $5.0 million Registered Direct Offering
- Nanjing, China, April 15, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced that it has entered into a securities purchase agreement with several investors for the purchase and sale of (i) 9,090,908 Class A ordinary shares (the “Class A Ordinary Shares”), par value $0.001 per share, of the Company; and (ii) Class A Ordinary Share purchase warrants to purchase up to 90,909,080 Class A Ordinary Shares (the “Warrants”); and (iii) up to 90,909,080 Class A Ordinary Shares issuable upon exercise of the Warrants. Each Class A Ordinary Share is being sold together with two associated Warrants, each to purchase one Class A Ordinary Share at a combined offering price of $0.55 per Class A Ordinary Share and associated Warrants.
- 04/15/2025
|
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive data in the prevention or delay of amputation during the treatment of primary osteosarcoma for OST-HER2 combined palliative radiation in dogs with unresected appendicular osteosarcoma. The treatment led to clinical and radiographic arrest of the primary tumor and prolonged time to metastasis.
- 04/10/2025
|
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
- Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of greater than 500 days in 5 out of 15 dogs. Data from new publication in the journal "Molecular Therapy" show OST-HER2 induces strong innate and cytotoxic immune responses beginning at the 1 st dose of 3 dose regimen, that correlate with prevention of metastasis and long-term survival in dogs with resected primary osteosarcoma.
- 04/10/2025
|
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has submitted a request for a formal meeting with the Center for Biologics Evaluation and Research (CBER) of the United States Food & Drug Administration (FDA) to gain alignment on the clinical endpoints required to support Breakthrough Therapy Designation (BTD) and Accelerated Approval v.
- 04/07/2025
|
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes (Lm) immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma. “We are making rapid progress in putting together an appropriate data package to achieve accelerated.
- 03/31/2025
|
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
- NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for.
- 03/25/2025
|
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
- NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company's Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma.
- 03/13/2025
|
OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting (SAM) in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway (ILAP) with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for OST-HER2, its immunotherapy candidate for the prevention of recu.
- 03/11/2025
|
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
- NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) that a patent will be issued covering the manufacturing methods required for the OST-HER2 commercial product. The USPTO granted a Patent Term Adjustment of 572 days, providing market exclusivity for the OS.
- 02/20/2025
|
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
- NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of OST-HER2. The Company is currently organizing additional data in relation to the recently-completed treatment phase of its Phase 2b trial of OST-HER2 in the prevention of recurrence of lung metastatic osteosarcoma in preparation for a.
- 02/14/2025
|
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
- On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.
- 01/15/2025
|
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
- NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company's HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res.
- 01/15/2025
|
Ostin Technology Group Announces Update to Effective Date of Reverse Share Split
- Nanjing, China, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced an update to the effective date of its previously approved reverse share split of the Company's Class A ordinary shares, with the split ratio set at 1-for-10 (the “Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The effective date for the Reverse Share Split has been revised from December 26, 2024 to December 31, 2024 and the Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 31, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
- 12/24/2024
|
Ostin Technology Group Announces Effective Date of Reverse Share Split
- Nanjing, China, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-10 (the “The Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 26, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
- 12/19/2024
|
Ostin Technology Group Announces Results of Extraordinary General Meeting
- Nanjing, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, announced the results of an Extraordinary General Meeting held on November 26, 2024, at 10:00 a.m. Beiijng Time (November 25, 2024, at 9:00 p.m., U.S. Eastern time) at its executive office at Floor 1, Building F4, 1 Zidong Road, Qixia District, Nanjing, Jiangsu Province, China.
- 11/27/2024
|
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
- NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dose. This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Ev.
- 08/29/2024
|
Ostin Technology Group Unveils Strategic Expansion into North American Market With its US Subsidiary Begins Operation
- Nanjing, China, April 10, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, announces that Pintura.Life LLC, the Company's wholly owned subsidiary in the United States (“Pintura.Life”), has officially commenced its operation.
- 04/10/2024
|
Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification letter has no current effect on the listing or trading of the Company's securities on the Nasdaq Capital Market, which will continue to trade uninterrupted on Nasdaq under the ticker "OST".
- 01/24/2024
|
Ostin Technology Group Announces Major Product Upgrade to Pintura Photo Sharing Product
- Nanjing, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces new upgrade to its photo sharing product, Pintura. The new upgrades will elevate user experience with improvements to both Pintura's hardware and software system. The Company plans to launch the upgraded Pintura product at the next Consumer Electronics Show (CES) in early 2024, which is also expected to be available for purchase through short-video platforms.
- 11/30/2023
|
Ostin Technology Group Co. Secured New Purchase Orders of Treadmill Screen Products; Officially Opens Douyin Store with Latest Smartwatch Products Now Available for Purchase
- Nanjing, China, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it has secured new purchase orders of nearly 5,000 “21.5-inch module” treadmill screen products from a leading fitness equipment manufacturer in China. The Company also unveiled the grand opening of its flagship Douyin store. This exciting launch unveils the M4 and GT8-PRO smartwatches, now available for purchase online.
- 10/09/2023
|
Ostin Technology Group Co., Ltd. to Hold Annual General Meeting of Shareholders on September 28, 2023
- Nanjing, China, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that it expects to hold its 2023 annual general meeting of shareholders on September 28, 2023 at 8:00 p.m., Beijing Time (September 28, 2023, at 8:00 a.m., Eastern Time), at its executive office at Building 2, 101/201, 1 Kechuang Road, Qixia District, Nanjing, Jiangsu Province, China 210046.
- 08/30/2023
|
Ostin Technology Group Plans to Launch New M4 and GT8-PRO Smartwatches Via Short-Video Platforms
- Nanjing, China, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced the Company plans to launch its new smartwatch products, M4 and GT8-PRO, through one of the most popular Chinese short-video platforms. These smartwatch products are expected to be officially available for purchase on Douyin (TikTok) platform in the third quarter this year. The Company is also expected to market and sell its smartwatch products through other popular short-video platforms, including Kuaishou (Kwai) and WeChat Channel.
- 08/10/2023
|
3 Cheap Stocks to Buy Under $1 in August 2023
- The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent.
- 08/04/2023
|
Ostin Technology Group Secures Orders for Metro Projects in Beijing, Tianjin, and Nanjing of China
- Nanjing, China, July 17, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that it has secured orders to purchase platform door displays, metro Passenger Information System (“PIS”) screens, and metro platform monitors, which are expected to be used for metro projects in Beijing, Tianjin, and Nanjing of China.
- 07/17/2023
|
Ostin Technology Group Debuts Photo Sharing Product Pintura
- NANJING, China, Sept. 30, 2022 (GLOBE NEWSWIRE) — Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, recently launched its first smart display and photo sharing product Pintura PinTab Series IX (“Pintura”). Pintura is a product based on artificial intelligence of things (AIoT) technologies, and is… The post Ostin Technology Group Debuts Photo Sharing Product Pintura appeared first on DKODING...
- 09/30/2022
|
Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now
- Penny stocks to buy: Here's what short interest traders think The post Best Penny Stocks To Buy: 4 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/08/2022
|
Ostin Technology Group Secures RMB17.64 Million LCD/TP Display Module Purchase Orders
- Nanjing, China, July 28, 2022 (GLOBE NEWSWIRE) — Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company has secured purchase orders for LCD/TP display modules of an aggregate value of RMB17.64 million (approximately $2.6 million). The display modules are expected to… The post Ostin Technology Group Secures RMB17.64 Million LCD/TP Display Module Purchase Orders appeared first on DKODING...
- 07/28/2022
|
3 Penny Stocks Exploding in Early May 2022
- Why these 3 penny stocks exploded today The post 3 Penny Stocks Exploding in Early May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/03/2022
|
